Continuing to bolster its early-stage pipeline, Biogen has partnered with Sangamo Therapeutics to develop gene editing treatments for neurology indications using the latter’s zinc finger nuclease technology. The deal, which is worth up to US$2.7 B, will focus initially on two preclinical assets, ST-501 and ST-502, as well as one undisclosed target. Biogen also has the right to nominate up to nine additional targets. Interestingly, the deal comes a year after two of Sangamo’s gene editing therapies revealed disappointing data in Phase I/II trials.